Jim Cramer says don't sell Meta on litigation risk — the stock is worth the wait

Bank of America said Meta’s California youth-addiction trial is only one “data point” in a long multi-jurisdiction litigation process, while reiterating a buy rating and $810 price target on shares around $560 (~45% upside). The advisory nature of the jury decision and dismissed claims reduce downside timing risk, but state AG litigation (29 states) could still lead to billions in damages and platform-altering remedies. Risk sentiment remains pressured—Meta is down 26% in 2026—though BofA argues “compelling valuation” (~16x estimated 2027 earnings) and AI-driven ad targeting/compute build-out help offset legal uncertainty.

Analysis

The market is still pricing this as a litigation headline, but the real risk is a future remedies regime that quietly degrades ad efficiency and engagement, not a one-time cash penalty. For META, that matters more than the size of any fine: even modest friction in targeting, format design, or user time-spent can pressure auction dynamics and force a lower multiple on forward earnings. Near term, the stock will trade on incremental court language; over 6-18 months, the question is whether legal outcomes cap the AI-driven rebound narrative by constraining product surface area.

If courts force product changes, ad dollars are likely to migrate first to Alphabet, then to smaller but cleaner inventory pools like SNAP and PINS, while Amazon Ads could capture incremental budgets from performance advertisers seeking scale without social-risk baggage. The second-order winner is not necessarily another social app; it is any platform with deterministic intent signals or less exposure to design-based litigation. Meta’s AI capex story also creates an asymmetric setup: if litigation limits monetization of the very engagement that AI is meant to improve, the market may keep assigning capex a low return multiple.

Contrarian view: consensus is probably overestimating the speed of cash damage and underestimating the durability of structural remedies. The bear case is not “billions in fines”; it is a slow-motion reduction in the quality of the feed and ad product that compresses ROIC for years. What would falsify that thesis is a narrow, advisory-only outcome with no meaningful injunction language and no appellate momentum; conversely, any judge-backed remedy tied to platform design would justify a materially lower valuation band.

Key Decisions for Investors

• Do not chase an outright short in META on trial headlines; the better risk/reward is to stay patient until legal language clarifies whether remedies are behavioral or merely financial. For existing longs, hedge into the next catalyst window with 1-3 month put spreads.
• Relative-value: long GOOGL / short META for 1-3 months. Thesis: if ad budgets rotate on any perceived weakening of Meta engagement tools, Alphabet captures the cleanest incremental spend while carrying far less litigation-specific multiple risk.
• Watch SNAP and PINS as secondary beneficiaries if Meta is forced into product changes. A small long basket can work as a spillover trade, but only if the case starts signaling design remedies rather than damages-only outcomes.
• Use a buy-the-dip framework on META only after a non-final selloff of roughly 8-10% on headline risk, with a 6-18 month horizon. The trade breaks if the court moves toward injunctions limiting engagement mechanics or if AI capex continues to outpace evidence of monetization.